Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MetaVia Inc

MTVA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.49

▲ +2.05%

Market Cap $9.82M · Vol 5.91K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$9.82M

Micro Cap

Div Yield

N/A

EPS Growth

+65.71%

YoY

RSI (14)

55.00

Momentum

Beta

0.90

vs Market

52W High

$18.92

92.12% below

52W Low

$0.97

53.61% above

Volume

5.91K

Avg 48.51K

P/B

3.64

Price-to-book

ROE

N/A

Return on equity

Free Float

71.39%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, MetaVia Inc (MTVA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MTVA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-22.80%

+25.21%

-9.15%

YTD

-82.30%

-78.84%

-97.26%

-99.98%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-12,973,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-94.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.64
P/FCF	N/A
EPS Growth	+65.71%
Outstanding Shares	6.59M

Technical Indicators

50-Day SMA	$1.64
200-Day SMA	$3.63
RSI (14)	55.00
Beta	0.90
52-Week High	$18.92
52-Week Low	$0.97

Volume Today	5.91K
Avg Daily Volume (30D)	48.51K
Relative Volume	0.12x
Volatility (10D)	41.71
Volatility (30D)	62.75
Free Float	71.39%

Analyst Consensus

BUY

Current Price $1.49

Mean Target $19.33

52W Low$0.97 52W High$18.92

Current

Target

$0.97 $18.92

Current Analyst target

+1,197.54% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG009YPPXS7

ISINUS64132R5037

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.